Scandinavian Journal of Rheumatology最新文献

{"title":"Pretreatment absolute monocyte counts are associated with biological disease-modifying anti-rheumatic drug non-response in patients with rheumatoid arthritis.","authors":"S F Ling, P Ho, M Bukhari, D Mewar, H Chinoy, A W Morgan, J D Isaacs, A G Wilson, K L Hyrich, A Barton, D Plant","doi":"10.1080/03009742.2025.2497606","DOIUrl":"https://doi.org/10.1080/03009742.2025.2497606","url":null,"abstract":"<p><strong>Objective: </strong>Previous publications have reported that increased absolute monocyte counts are associated with treatment non-response in patients with rheumatoid arthritis (RA). This study investigated whether full blood count (FBC) components from routine clinical testing before treatment with a biological disease-modifying anti-rheumatic drug (bDMARD) were associated with treatment non-response after 6 months of treatment.</p><p><strong>Method: </strong>From a UK-based prospective multicentre study of patients with RA starting a bDMARD, data from 246 patients attending five of the participating centres were retrieved. FBC components were analysed for their association with European Alliance of Associations for Rheumatology non-response after 6 months of treatment using backward stepwise logistic regression, adjusting for potential confounders. Final models underwent resampling with 200 repeats of out-of-bag bootstrapping to assess model performance using area under the receiver operating characteristics (AUROC) curves. Model fit was compared using the Akaike information criterion (AIC).</p><p><strong>Results: </strong>After 6 months of treatment, the only FBC component predictive of non-response was pretreatment absolute monocyte count [adjusted odds ratio (OR_adj) 9.56, 95% confidence intervals (CI) 1.61-59.86, p = 0.01, AUROC = 60.42%). The model including monocytes as a predictor demonstrated superior performance to the covariates-only model (AIC 184.36 vs 188.51, respectively).</p><p><strong>Conclusion: </strong>In the largest study to date, increasing absolute monocyte counts were associated with bDMARD non-response after 6 months of treatment, replicating previous reports. Validation and mechanistic studies are required to inform future treatment selection.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-6"},"PeriodicalIF":2.2,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synovial chondromatosis in a patient with atypical rheumatoid arthritis confirmed by clinical, radiographic, and pathological evidence: a case report.","authors":"C H Li, J L Gao, C Ren, S M Yang, Y Y Hou, Z H He, J X Zhao, Y P Yang","doi":"10.1080/03009742.2025.2491181","DOIUrl":"https://doi.org/10.1080/03009742.2025.2491181","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-3"},"PeriodicalIF":2.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Late-onset Raynaud's phenomenon in a 90-year-old male with polymyalgia rheumatica.","authors":"A Nigro","doi":"10.1080/03009742.2025.2491875","DOIUrl":"https://doi.org/10.1080/03009742.2025.2491875","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-3"},"PeriodicalIF":2.2,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143992636","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Osteitis condensans ilii: a mimicker of axial spondyloarthritis.","authors":"S Uslu","doi":"10.1080/03009742.2025.2495493","DOIUrl":"https://doi.org/10.1080/03009742.2025.2495493","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-2"},"PeriodicalIF":2.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144031455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-inflammatory macrophages phagocytose and hydrolyse monosodium urate crystals in different stages of gout.","authors":"Y-J Huang, L-C Wang, C-P Wang, K-H Yu, C-F Kuo","doi":"10.1080/03009742.2025.2491176","DOIUrl":"https://doi.org/10.1080/03009742.2025.2491176","url":null,"abstract":"<p><strong>Objective: </strong>Macrophages play a crucial role in gouty arthritis; however, the relationship between non-inflammatory macrophages (M0) and different stages of gout remains unclear. This study aimed to investigate the phagocytosis, hydrolysis, and subsequent cytokine secretion of monosodium urate (MSU) by non-inflammatory macrophages in patients in different stages of gout.</p><p><strong>Method: </strong>Non-inflammatory macrophages were derived from monocytes through stimulation with macrophage colony-stimulating factor (M-CSF) for a duration of 10 days. The study included patients with asymptomatic hyperuricaemia, intercritical gout, tophaceous gout, and a normal control group. The phagocytic and hydrolytic capabilities of non-inflammatory macrophages were measured using flow cytometry based on the increase in side-scatter area. In addition, to evaluate the relationship between the hydrolysis capability of non-inflammatory macrophages and subsequent inflammation, we cultured them with lipopolysaccharide (LPS) and/or MSU.</p><p><strong>Results: </strong>We discovered that M0 macrophages were capable of phagocytosing and hydrolysing MSU crystals in various stages of gout, including the control group. Patients with asymptomatic hyperuricaemia exhibited the most pronounced phagocytic and hydrolytic capabilities, surpassing even those of the normal control group. The presence of MSU alone did not induce the secretion of pro-inflammatory cytokines. However, in experiments where M0 macrophages were stimulated with LPS and/or MSU, the phagocytic and hydrolytic abilities of M0 macrophages were correlated with inflammatory cytokine elevation.</p><p><strong>Conclusion: </strong>The efficient phagocytosis and hydrolysis of MSU crystals by M0 macrophages suggest their role in maintaining the non-inflammatory stage of gout. Our findings suggest that non-inflammatory macrophages play a role in gout.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-10"},"PeriodicalIF":2.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dysregulated serum lipid profile and atherosclerosis in untreated female Takayasu arteritis patients: a propensity score-matched analysis.","authors":"Q Zang, F Li, Y Ju, J Wang, J Luo, W Liu, T Ding, L He, L Mo","doi":"10.1080/03009742.2025.2488096","DOIUrl":"https://doi.org/10.1080/03009742.2025.2488096","url":null,"abstract":"<p><strong>Objective: </strong>Recent studies suggest that dyslipidaemia may play a critical role in the progression of cardiovascular disease in Takayasu arteritis (TA), although the exact relationship between dyslipidaemia and TA disease activity remains unclear, which is the focus of this study.</p><p><strong>Method: </strong>We evaluated dyslipidaemia and atherosclerosis in a cohort of untreated female patients. Fifty untreated female patients with TA (median age 30 years) and 98 healthy controls matched for age and body mass index (median age 30 years) were assessed for lipid profiles [total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A1 (ApoA1), ApoB, ApoE, lipoprotein(a)], inflammatory markers [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR)], and atherosclerotic plaque frequency.</p><p><strong>Results: </strong>TA patients exhibited significantly higher levels of TG and the non-HDL-C/HDL-C ratio than the control group, whereas TC, HDL-C, LDL-C, and ApoA1 levels were significantly lower. Pearson's correlation analysis indicated a positive correlation between CRP and ApoB, as well as the non-HDL-C/HDL-C ratio, and negative correlations with TG, HDL-C, and ApoA1. Atherosclerotic plaques were detected in 14.3% of the TA patients. Multivariate regression analysis revealed that the presence of atherosclerotic plaques was associated only with age, independent of inflammatory markers and lipoprotein levels.</p><p><strong>Conclusion: </strong>The results of this study indicate that untreated female TA patients exhibit a markedly dysregulated serum lipid profile. Atherosclerosis in early TA was not related to lipids or markers of inflammation.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-9"},"PeriodicalIF":2.2,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144009876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study.","authors":"A Kim, S C Kim, J Kim, M W So, S-G Lee","doi":"10.1080/03009742.2025.2467556","DOIUrl":"10.1080/03009742.2025.2467556","url":null,"abstract":"<p><strong>Objective: </strong>To compare the risk of cardiovascular disease (CVD) and gastrointestinal bleeding (GIB) between celecoxib and non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) in patients with ankylosing spondylitis (AS).</p><p><strong>Method: </strong>In this nationwide retrospective cohort study using the Korean Health Insurance Review and Assessment database, adult AS patients who received newly prescribed non-steroidal anti-inflammatory drugs (NSAIDs) continuously for ≥ 30 days (celecoxib or nsNSAIDs) between 2013 and 2017 were evaluated. The co-primary outcomes were the occurrence of composite CVD events, including hospitalization for myocardial infarction, ischaemic heart disease, stroke, transient ischaemic attack, heart failure, and coronary revascularization; and composite GIB, including hospitalization for upper and lower GIB. Propensity score (PS) matching was used to correct for baseline differences between the celecoxib- and nsNSAID-treated groups.</p><p><strong>Results: </strong>We identified 3164 celecoxib-treated and 18924 nsNSAID-treated patients with AS. After 1:1 PS matching, 3047 patients with AS were assigned to each of the celecoxib- and nsNSAID-treated groups. The incidence of composite CVD and GIB was 18.2/1000 person-years and 6.5/1000 person-years in celecoxib-treated and 15.1/1000 person-years and 7.3/1000 person-years in nsNSAID-treated patients, respectively. Compared to the nsNSAID-treated group, the hazard ratios of composite CVD and GIB in the celecoxib-treated group were not significant, with values of 1.17 (p = 0.499) and 0.87 (p = 0.696), respectively. There were no significant differences in the risk of each component of the composite CVD and GIB between the two groups.</p><p><strong>Conclusion: </strong>We did not find significant differences in the risks of CVD and GIB between celecoxib and nsNSAIDs in AS patients.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"204-212"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143543378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of clinical variables with methotrexate response in patients with psoriatic arthritis.","authors":"F R Kasiem, L J Tucker, L C Coates, J J Luime, I Tchetverikov, M Vis, Jmw Hazes, M R Kok","doi":"10.1080/03009742.2025.2455885","DOIUrl":"10.1080/03009742.2025.2455885","url":null,"abstract":"<p><strong>Objective: </strong>Methotrexate (MTX) is widely used as first-line treatment in psoriatic arthritis (PsA). Despite the variable efficacy of MTX in PsA compared to newer therapeutic agents, its affordability and availability make it crucial, especially in resource-limited healthcare settings. Identification of factors associated with MTX non-response could facilitate early redirection to more effective therapy. This study aimed to identify baseline clinical, demographic, and psychosocial variables associated with non-response 3 months after MTX initiation in a real-world, treatment-naïve PsA patient cohort.</p><p><strong>Method: </strong>Recently diagnosed, disease-modifying anti-rheumatic drug-naïve PsA patients were included. Treatment response was defined by attaining minimal disease activity 3 months after initiation of MTX monotherapy. A multivariate logistic regression analysis was performed, including sensitivity analysis. Missing variables were imputed through multiple imputations.</p><p><strong>Results: </strong>In total, 287 patients were included, of whom 199 (69%) were non-responders. The median dose of MTX was 19.5 (interquartile range 15-25) mg/week. Worse baseline functioning (Health Assessment Questionnaire) [odds ratio (OR) 0.28, 95% confidence interval (CI) 0.13-0.60], higher tender joint count in 68 joints (OR 0.91, 95% CI 0.84-0.97), and higher depression scores (Hospital Anxiety and Depression Scale) (OR 0.88, 95% CI 0.78-0.99) were associated with a lower response rate to MTX at 3 months.</p><p><strong>Conclusion: </strong>Our findings highlight the need for a comprehensive approach to managing patients with PsA. This involves addressing modifiable risk factors, such as depression, alongside controlling PsA disease activity. Further research is warranted to evaluate whether this integrated strategy could improve treatment efficacy and overall patient outcomes.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"184-191"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143415091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"No association between vascular inflammation and estimated glomerular filtration rate in patients with rheumatoid arthritis: secondary analysis of the TARGET trial.","authors":"S Fukui, A Tawakol, W C Winkelmayer, L M Santacroce, J T Giles, K P Liao, J M Bathon, D H Solomon","doi":"10.1080/03009742.2025.2455878","DOIUrl":"10.1080/03009742.2025.2455878","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"213-216"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12014359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global health in axial spondyloarthritis: thresholds for the Assessment of SpondyloArthritis international Society Health Index and the EuroQol score: analysis of the ASAS-PerSpA study.","authors":"Jms Drouet, C López-Medina, A Molto, B Granger, B Fautrel, C Gaujoux-Viala, U Kiltz, M Dougados, L Gossec","doi":"10.1080/03009742.2024.2424085","DOIUrl":"10.1080/03009742.2024.2424085","url":null,"abstract":"<p><strong>Objectives: </strong>In axial spondyloarthritis (axSpA), patient-perceived quality of life/global functioning and health (GH) can be assessed using disease-specific [Assessment of SpondyloArthrit is international Society Health Index (ASAS-HI)] or generic [(3-level EuroQol 5 Dimensions (EQ-5D-3L)] scores. Our objectives were to explore the link between these scores and to define thresholds for good and poor GH.</p><p><strong>Method: </strong>We conducted a post-hoc analysis of the cross-sectional ASAS-PerSpA study for patients fulfilling ASAS criteria for axSpA. The ASAS-HI and EQ-5D scores were analysed visually (distribution, scatterplot) and through Spearman correlation and agreement (deciles). To determine cut-offs for good and poor GH on EQ-5D based on the validated ≤5 and ≥12 cut-offs for ASAS-HI, respectively, receiver operating characteristics (ROC) curves and distribution-based methods were applied. Validity was assessed using crude concordance and prevalence-adjusted bias-adjusted kappa; discordance between groups was explored.</p><p><strong>Results: </strong>In 2651 patients (median age 41.0 years, 66.5% men), the correlation between ASAS-HI and EQ-5D was high (r = -0.73) and agreement (between deciles) was moderate (weighted kappa = 0.51). Both ROC areas under the curve were 0.86; thresholds of 0.69 and 0.54 for EQ-5D were chosen for good and poor GH, respectively. Crude concordances and agreement were satisfactory (0.80-0.81 and 0.60-0.61, respectively). The EQ-5D cut-off for good GH performed better than that for poor GH.</p><p><strong>Conclusion: </strong>ASAS-HI and EQ-5D were highly correlated but did not fully overlap. We propose EQ-5D thresholds corresponding to the ASAS-HI thresholds for good and poor GH; however, caution is needed when assessing poor GH with EQ-5D. These findings will be useful to compare GH when only one of the outcome measures is available.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"175-183"},"PeriodicalIF":2.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}